FrancophonIA/ELRC3.0 huggingface dataset:
English: A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A) ....... 15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B) .
Estonian: A/California/7/2009 (H1N1)pdm09 - sarnane tüvi (A/California/7/2009, NYMC X-179A) .......... 15 mikrogrammi HA** A/Hong Kong/4801/2014 (H3N2) - sarnane tüvi (A/Hong Kong/4801/2014, NYMC X-263B) ..... 15 mikrogrammi HA** B/Brisbane/60/2008 - sarnane tüvi (B/Brisbane/60/2008, metsikut tüüpi) ...................................... 15 mikrogrammi HA**
English: --1 Influenza virus (inactivated, split) of the following strains*:
Estonian: Gripiviiruse (inaktiveeritud, purustatud) järgmised tüved*:
English: Per 0.1 ml dose * propagated in fertilised hens' eggs from healthy chicken flocks ** haemagglutinin l t o r
Estonian: 0,1 ml annuse kohta * saadud viljastatud, tervete kanade munadelt ** hemaglutiniin l n a
English: Invented name Strength
Estonian: Manustamistee Pakendi iseloomustus
English: A risk management plan has been developed to ensure that PritorPlus is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada PritorPlusi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of PritorPlus?
Estonian: Mis meetmed võetakse, et tagada PritorPlusi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for PritorPlus on 22 April 2002.
Estonian: Euroopa Komisjon andis PritorPlusi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 22. Aprillil 2002.
English: The full EPAR for PritorPlus can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst PritorPlusi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: PritorPlus is taken by mouth once a day with liquid, with or without food.
Estonian: PritorPlusi võetakse suu kaudu üks kord ööpäevas koos vedelikuga, koos toiduga või ilma.
English: Other information about PritorPlus
Estonian: Muu teave PritorPlusi kohta
English: PritorPlus has been studied in five main studies involving a total of 2,985 patients with mild to moderate hypertension.
Estonian: PritorPlusi uuriti viies põhiuuringus, milles osales kokku 2985 kerge kuni mõõduka hüpertensiooniga patsienti.
English: The Committee recommended that PritorPlus be given marketing authorisation.
Estonian: Komitee soovitas anda PritorPlusi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for PritorPlus.
Estonian: See on ravimi PritorPlus Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for PritorPlus.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, PritorPlus must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Estonian: II tüüpi diabeediga patsiendid või mõõduka kuni raske neerukahjustusega patsiendid ei tohi PritorPlusi kasutada koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: The most common side effect with PritorPlus (seen in between 1 and 10 patients in 100) is dizziness.
Estonian: PritorPlusi kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on peapööritus.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for PritorPlus, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati PritorPlusi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is PritorPlus?
Estonian: Mis on PritorPlus?
English: Care must be taken when using PritorPlus with other medicines that have an effect on blood potassium levels.
Estonian: Ettevaatlik tuleb olla PritorPlusi kasutamisel koos teiste ravimitega, mis võivad mõjutada vere kaaliumisisaldust.
English: For more information about treatment with PritorPlus, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate PritorPlusiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is available as tablets (40 or 80 mg telmisartan and 12.5 mg hydrochlorothiazide; 80 mg telmisartan and 25 mg hydrochlorothiazide).
Estonian: Ravimit turustatakse tablettidena (40 mg või 80 mg telmisartaani ja 12,5 mg hüdroklorotiasiidi; 80 mg telmisartaani ja 25 mg hüdroklorotiasiidi).
English: PritorPlus was more effective at reducing diastolic blood pressure than telmisartan taken alone and than placebo.
Estonian: PritorPlus vähendas diastoolset vererõhku paremini kui eraldi manustatud telmisartaan ja platseebo.
English: Why has PritorPlus been approved?
Estonian: Miks PritorPlus heaks kiideti?
English: PritorPlus telmisartan / hydrochlorothiazide
Estonian: PritorPlus telmisartaan/hüdroklorotiasiid
English: What is the risk associated with PritorPlus?
Estonian: Mis riskid PritorPlusiga kaasnevad?
English: PritorPlus is a medicine that contains two active substances, telmisartan and hydrochlorothiazide.
Estonian: PritorPlus on ravim, mis sisaldab kaht toimeainet: telmisartaani ja hüdroklorotiasiidi.
English: In four of these studies, PritorPlus was compared with placebo (a dummy treatment) and with telmisartan taken alone in a total of 2,272 patients.
Estonian: Neist neljas uuringus võrreldi kokku 2272 patsiendil PritorPlusi mõju platseebo (näiva ravimi) ja ainult telmisartaani mõjuga.
English: PritorPlus must also not be used in people who have severe liver, kidney or bile problems, blood potassium levels that are too low, or blood calcium levels that are too high.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on raske maksa-, neeru- või sapihaigus, liiga väike kaaliumisisaldus või liiga suur kaltsiumisisaldus veres.
English: PritorPlus is used in adult patients who have essential hypertension (high blood pressure) that is not adequately controlled by telmisartan alone.
Estonian: PritorPlusi kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) täiskasvanud patsientidel, kelle vererõhku ei saa ainult telmisartaaniga piisavalt reguleerida.
English: The 80/25 mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5 mg tablets or who have been stabilised using the two active substances taken separately before switching to PritorPlus.
Estonian: 80/25 mg tablette kasutatakse patsientidel, kelle vererõhk ei allu ravile 80/12,5 mg tablettidega või kelle vererõhk on enne PritorPlusile üleminekut kahe toimeaine eraldi manustamise abil stabiliseerunud.
English: PritorPlus must not be used in women who are more than three months pregnant.
Estonian: Ravimit ei tohi kasutada rasedad pärast esimest kolme raseduskuud.
English: PritorPlus contains two active substances, telmisartan and hydrochlorothiazide.
Estonian: PritorPlus sisaldab kaht toimeainet: telmisartaani ja hüdroklorotiasiidi.
English: For the full list of all side effects reported with PritorPlus, see the package leaflet.
Estonian: PritorPlusi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The dose of PritorPlus to be used depends on the dose of telmisartan that the patient was taking before: patients who were receiving 40 mg telmisartan should take the 40/12.5 mg tablets, and patients who were receiving 80 mg telmisartan should take the 80/12.5 mg tablets.
Estonian: PritorPlusi annus sõltub patsiendi varasemast telmisartaani annusest: 40/12,5 mg tablette antakse patsientidele, kes said varem 40 mg telmisartaani, ja 80/12,5 mg tablette patsientidele, kes said varem 80 mg telmisartaani.
English: The CHMP decided that PritorPlus's benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on telmisartan alone.
Estonian: Inimravimite komitee otsustas, et PritorPlusi kasulikkus nende essentsiaalse hüpertensiooniga patsientide ravis, kelle vererõhku ei saa ainult telmisartaaniga piisavalt reguleerida, on suurem kui ravimiga kaasnevad riskid.
English: What benefit has PritorPlus shown during the studies?
Estonian: Milles seisneb uuringute põhjal PritorPlusi kasulikkus?
English: How is PritorPlus used?
Estonian: Kuidas PritorPlusi kasutatakse?
English: How does PritorPlus work?
Estonian: Kuidas PritorPlus toimib?
English: What is PritorPlus used for?
Estonian: Milleks PritorPlusi kasutatakse?
English: How has PritorPlus been studied?
Estonian: Kuidas PritorPlusi uuriti?
English: Treatment can be repeated every three months if necessary.
Estonian: Ravi võib vajaduse korral korrata iga kolme kuu järel.
English: Visudyne verteporfin
Estonian: Visudyne verteporfiin
English: The European Commission granted a marketing authorisation valid throughout the European Union for Visudyne on 27 July 2000.
Estonian: Euroopa Komisjon andis Visudyne müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. juulil 2000.
English: Although the first study in occult disease showed some effectiveness, this was not confirmed in the second study.
Estonian: Kuigi esimeses varjatud haigusega patsientide uuringus ilmnes teatav efektiivsus, ei kinnitanud seda teine uuring.
English: If necessary, the other eye can be treated with the laser immediately afterwards.
Estonian: Vajaduse korral võib teist silma laseriga ravida kohe esimese järel.
English: The full EPAR for Visudyne can be found can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Visudyne kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In all three studies, the main measure of effectiveness was the number of patients who had responded to treatment after a year, measured using a standard eye test chart.
Estonian: Kõigis kolmes uuringus oli efektiivsuse põhinäitaja nende patsientide arv, kellel oli aasta pärast tekkinud ravivastus, mida hinnati standardse silmakontrollitabeli abil.
English: The most common side effects with Visudyne (seen in between 1 and 10 patients in 100) are hypercholesteraemia (high blood cholesterol levels), hypersensitivity (allergic reactions), severely reduced visual acuity (very unclear vision), visual impairment (such as unclear vision, blurred fuzzy vision or flashes of light), defects in the visual field (such as small areas of reduced vision, grey or dark haloes, and black spots), dyspnoea (shortness of breath), nausea (feeling sick), photosensitivity reactions (sunburn-like reactions following exposure to light), reactions at the injection site (pain, swelling, inflammation and leakage of fluid from the veins), asthenia (weakness), infusion-related pain (mainly chest and back pain), syncope (fainting), headache and dizziness.
Estonian: Visudyne kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on hüperkolestereemia (vere suur kolesteroolisisaldus), ülitundlikkus (allergiareaktsioonid), tugevasti vähenenud nägemisteravus, nägemishäired (nt ähmane, udune, ebaselge nägemine, valgussähvatused), vaatevälja defektid (nt halvenenud nägemisega piirkonnad, hallid või tumedad ringid ja mustad laigud), düspnoe (raskendatud hingamine), iiveldus, valgustundlikkusreaktsioonid (päikesepõletuse sarnased reaktsioonid valguse käes olnud nahapiirkonnal), infusioonikoha reaktsioonid (valu, turse, põletik ja vedeliku imbumine veenist), nõrkus, infusiooniga seotud valu (peamiselt rindkere- ja seljavalu), minestus, peavalu ja peapööritus.
English: A patient was classified as a responder if the number of letters that they could see increased, stayed the same, or fell by less than 15.
Estonian: Ravivastus loeti tekkinuks, kui patsiendi nähtud tähtede arv oli suurem, jäi samaks või vähenes vähem kui 15 võrra.
English: The dose depends on the body surface area (calculated using the patient's height and weight).
Estonian: Annus sõltub kehapindalast (arvutatakse patsiendi pikkuse ja kehamassi järgi).
English: The CHMP decided that Visudyne's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Visudyne kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Some of these patients went on to receive Visudyne for up to five years.
Estonian: Mõni patsient kasutas Visudynet kuni 5 aastat.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Visudyne.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of restrictions and side effects reported with Visudyne, see the package leaflet.
Estonian: Visudyne kohta teatatud piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For more information about treatment with Visudyne, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Visudynega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: When the laser light is shone into the eye, verteporfin is activated and generates toxic oxygen molecules which block blood vessels, damage and even kill cells.
Estonian: Laserkiirguse juhtimisel silma verteporfiin aktiveerub ja tekitab toksilisi hapnikumolekule, mis blokeerivad veresooni ning kahjustavad ja hävitavad rakke.
English: Other information about Visudyne:
Estonian: Muu teave Visudyne kohta
English: This was followed by a confirmatory study in a further 364 patients that was carried out at the request of the CHMP.
Estonian: Sellele järgnes inimravimite komitee nõudel kinnitav uuring veel 364 patsiendiga.
English: The second step, 15 minutes after the start of the infusion, is the activation of Visudyne in the eye using light generated by a laser beam.
Estonian: Seejärel, 15 minutit pärast infusiooni algust, aktiveeritakse Visudyne silmas laserkiirguse abil.
English: Visudyne is used when the neovascularisation is subfoveal
Estonian: Visudynet kasutatakse, kui neovaskularisatsioon on subfoveaalne.
English: The benefit of Visudyne was maintained for up to five years for both diseases.
Estonian: Visudyne ravitoime püsis mõlema haiguse korral kuni 5 aastat.
English: The benefit of Visudyne in occult subfoveal choroidal neovascularisation has not been established.
Estonian: Visudyne kasulikkus soonkesta varjatud subfoveolaarse neovaskularisatsiooni ravis ei ole tõendatud.
English: Visudyne has been compared with placebo (a dummy treatment) in two studies involving a total of 609 AMD patients with classic subfoveal neovascularisation, and in one study involving 120 patients with neovascularisation caused by pathologic myopia.
Estonian: Visudynet võrreldi platseeboga (näiva ravimiga) kahes uuringus, milles osales kokku 690 makula ealise degeneratsiooniga ja klassikalise subfoveolaarse neovaskularisatsiooniga patsienti, ning ühes uuringus, kus osales 120 patoloogilisest müoopiast tingitud neovaskularisatsiooniga patsienti.
English: This document is a summary of the European Public Assessment Report (EPAR) for Visudyne.
Estonian: Käesolev dokument on ravimi Visudyne Euroopa avaliku hindamisaruande kokkuvõte.
English: Visudyne is a medicine that contains the active substance verteporfin.
Estonian: Visudyne on ravim, mis sisaldab toimeainena verteporfiini.
English: Treatment with Visudyne is a two-step process.
Estonian: Ravi Visudynega toimub kahes järgus.
English: What is Visudyne?
Estonian: Mis on Visudyne?
English: Visudyne must not be used in patients with porphyria (an inability to break down chemicals called porphyrins) or in patients with severe liver disease.
Estonian: Visudynet ei tohi kasutada patsiendid, kellel on porfüüria (haigus, mille korral porfüriinid organismis ei lagune) või kellel on raske maksahaigus.
English: • choroidal neovascularisation caused by pathologic myopia (a severe type of short-sightedness where the eyeball continues to grow, becoming longer than it should be).
Estonian: • Soonkesta neovaskularisatsioon, mille on põhjustanud patoloogiline müoopia (raske lühinägevuse vorm, kui silmamuna jätkab kasvamist pikisuunas).
English: The wet form of AMD is caused by choroidal neovascularisation (abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling.
Estonian: Makula ealise degeneratsiooni märga vormi põhjustab koroidaalne neovaskularisatsioon (ebanormaalsete veresoonte moodustumine kollastähni all), mis võib eritada vedelikku ja verd ning tekitada turset.
English: Visudyne has also been compared with placebo in ‘occult' subfoveal choroidal neovascularisation (when the blood vessels affected are not well defined on the scan), in a two-year study involving 339 patients.
Estonian: Visudynet võrreldi platseeboga ka soonkesta varjatud subfoveolaarse neovaskularisatsiooni (kui tekkinud veresooned ei ole uuringul selgesti tuvastatavad) 2-aastases uuringus, milles osales 339 patsienti.
English: Visudyne is used when the neovascularisation is ‘predominantly classic' (when the blood vessels affected are well defined on an eye scan) and subfoveal (occurs in the area under the fovea - the central area of the macula);
Estonian: Visudynet kasutatakse, kui neovaskularisatsioon on valdavalt klassikaline (kui kahjustatud veresooned on silmauuringuga hästi tuvastatavad) ja subfoveaalne (esineb kollastähni kesklohu all).
English: What is the risk associated with Visudyne?
Estonian: Mis riskid Visudynega kaasnevad?
English: Visudyne is used to treat adults with:
Estonian: Visudynet kasutatakse täiskasvanutel järgmiste haiguste raviks.
English: It is used in ‘photodynamic therapy', a method of treatment that uses light (generally from a laser) to activate a photosensitising agent.
Estonian: Seda kasutatakse fotodünaamilises ravis (ravimeetod, kus valgustundlik aine aktiveeritakse valgusega, tavaliselt laserkiirgusega).
English: In the two studies of wet AMD, 61% of the patients receiving Visudyne had responded to treatment after a year (246 out of 402), compared with 46% of those receiving placebo (96 out of 207).
Estonian: Makula ealise degeratsiooni märja vormi mõlemas uuringus oli patsiente, kellel tekkis ühe aasta jooksul ravivastus, Visudyne uuringurühmas 61% (246 patsienti 402st) ja platseeborühmas 46% (96 patsienti 207st).
English: When Visudyne is injected into a patient, verteporfin is distributed within the body through the blood vessels, including the blood vessels at the back of the eye.
Estonian: Visudyne süstimisel patsiendile levib verteporfiin organismis veresoonte, sealhulgas silma tagaosa veresoonte kaudu.
English: Why has Visudyne been approved?
Estonian: Miks Visudyne heaks kiideti?
English: First, the patient receives Visudyne as an infusion into a vein lasting 10 minutes.
Estonian: Kõigepealt manustatakse Visudynet 10 minutit kestva veeniinfusioonina.
English: In the study of pathologic myopia, 86% of the patients receiving Visudyne had responded after a year (70 out of 81), compared with 67% of those receiving placebo (26 out of 39).
Estonian: Patoloogilise müoopia uuringus oli patsiente, kellel tekkis ühe aasta jooksul ravivastus, Visudyne uuringurühmas 86% (70 patsienti 81st) ja platseeborühmas 67% (26 patsienti 39st).
English: This helps to close up the abnormal blood vessels that cause AMD.
Estonian: See aitab sulgeda ebanormaalseid veresooni, mis põhjustavad makula ealist degeneratsiooni.
English: The active substance in Visudyne, verteporfin, is a photosensitising agent (a substance that changes when exposed to light).
Estonian: Visudyne toimeaine verteporfiin on valgustundlik aine (aine, mis valguse mõjul muundub).
English: What is Visudyne used for?
Estonian: Milleks Visudynet kasutatakse?
English: How is Visudyne used?
Estonian: Kuidas Visudynet kasutatakse?
English: How does Visudyne work?
Estonian: Kuidas Visudyne toimib?
English: Visudyne should only be given by ophthalmologists (eye specialists) who have experience in the management of patients with AMD or pathological myopia.
Estonian: Visudynet tohib manustada üksnes makula ealise degeneratsiooni või patoloogilise müoopia ravis kogenud oftalmoloog (silmaarst).
English: How has Visudyne been studied?
Estonian: Kuidas Visudynet uuriti?
English: It is available as a powder that is made up into a solution for infusion (drip) into a vein.
Estonian: Visudynet turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: Visudyne was more effective than placebo in the studies of AMD and pathologic myopia.
Estonian: Makula ealise degeneratsiooni ja patoloogilise müoopia uuringus oli Visudyne platseebost efektiivsem.
English: What benefit has Visudyne shown during the studies?
Estonian: Milles seisneb uuringute põhjal Visudyne kasulikkus?
English: The medicine can only be obtained with a prescription.
Estonian: Visudyne on retseptiravim.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 15 June 2012
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 15. juuni 2012
English: Justification for not including Braille is accepted
Estonian: Põhjendus Braille mitte lisamiseks on vastuvõetav
English: They may decide to stop the infusion.
Estonian: Ta võib otsustada infusiooni katkestada.
English: For all patients:
Estonian: Kõik patsiendid:
English: Fe or
Estonian: Fe või
English: Re-treatment / Long term use
Estonian: Korduv ravi/pikaaegne kasutamine
English: One of these three cases was also characterized as an anaphylactoid reaction.
Estonian: Üht neist kolmest juhtumist iseloomustati ka anafülaktoidse reaktsioonina.
English: FREQUENCY NOT KNOWN (CANNOT BE ESTIMATED FROM AVAILABLE DATA)
Estonian: ESINEMISSAGE DUS TEADMATA (ei saa hinnata olemasolevate andmete alusel)
English: The following information is intended for healthcare professionals only (see Section 3):
Estonian: Järgmine teave on ainult tervishoiutöötajatele (vt lõik 3):
English: You will be lying down and your blood pressure and pulse will be monitored.
Estonian: Te lamate ja teil jälgitakse vererõhku ja pulssi.
English: Immunologic Disease or Infection
Estonian: Immunoloogiline haigus või infektsioon
English: 31 July 2016
Estonian: 31. juuli 2016
English: A careful risk/benefit evaluation is therefore required before use during pregnancy and Rienso should not be used during pregnancy unless clearly necessary (see section 4.4).
Estonian: Seetõttu on vajalik hoolikas riski/kasu hindamine enne raseduse ajal kasutamist ja Riensot ei tohi kasutada raseduse ajal, kui ei ole tingimata vajalik (vt lõik 4.4).
English: 31 October 2016
Estonian: 31. oktoober 2016
English: 29 of them were associated with hypersensitivity reactions.
Estonian: 29 neist olid seotud ülitundlikkusreaktsioonidega.
English: The principal efficacy results at Day 35 from the controlled phase of each study are shown in Table 3.
Estonian: Põhilised tulemused efektiivsuse osas 35. päevaks alates iga uuringu kontrollitud faasist on esitatud tabelis 3.
English: Administration should be performed as follows:
Estonian: Manustamine toimub järgmiselt:
English: In total 42 fatal cases have been reported cumulatively.
Estonian: Kokku on kumulatiivselt esinenud 42 surmaga lõppenud juhtu.